On February 19th, 2020, National Health Commission of the People\'s Republic of China issued the *Diagnosis and Treatment Plan of Corona Virus Disease 2019* (*Tentative Sixth Edition*). And now, it is interpreted as follows.

1. Route of transmission {#s0005}
========================

"Corona Virus Disease 2019 (COVID-19) is mainly transmitted by respiratory droplets and contact" is changed to "COVID-19 is mainly transmitted by respiratory droplets and close contact", in other words, "close" has been added in front of "contact". Besides, "Aerosol transmission is possible when humans have prolonged exposure to high concentrations of aerosol in a relatively closed space" is added.

2. Epidemiological characteristics {#s0010}
==================================

In severe cases, in addition to "rapidly progressing to acute respiratory distress syndrome, septic shock, difficult to correct metabolic acidosis, and hemorrhage and coagulation dysfunction", "multiple organ failure" can also occur in the worse.

As for laboratory examination, it is emphasized that "To improve the positive rate of nucleic acid detection, it is recommended to collect and retain sputum in general patients except those performed with tracheal intubation (lower respiratory tract secretions should be collect); and all the specimens should be sent and tested as fast as possible."

3. Case diagnosis {#s0015}
=================

Differences of diagnosis criteria between Hubei Province and other provinces were deleted and unified as "suspected cases" and "confirmed cases".

There are two judgements of suspected cases. First, "patients meet any one of the epidemiological exposure histories as well as any two of the clinical manifestations (fever and/or respiratory symptoms; having the imaging features of pneumonia mentioned above; in the early stage, a normal or decrease of total white blood cells count and a decrease of lymphocyte count can be found)". Second, "patients without definite epidemiological exposure history but meet the three clinical manifestations (fever and/or respiratory symptoms; having the imaging features of pneumonia mentioned above; in the early stage, a normal or decrease of total white blood cells count and a decrease of lymphocyte count can be found)".

Positive pathogen evidences are required for confirmed cases (a positive result of the nucleic acid of the novel coronavirus 2019 (2019-nCoV, officially named as severe acute respiratory syndrome coronavirus 2 \[SARS-CoV-2\] by International Committee on Taxonomy of Viruses) by real-time fluorescence reverse transcription-polymerase chain reaction (RT-PCR), or the virus gene sequence is highly homologous to the known 2019-nCoV).

4. Clinical classifications {#s0020}
===========================

Cases are still divided into mild cases, ordinary cases, severe cases and critical cases. "For high altitude areas (above 1 kilometer), PaO~2~/FiO~2~ values should be adjusted based on equation of PaO~2~/FiO~2~×\[Atmospheric Pressure (mmHg)/760\]" is added in the description of arterial partial pressure of oxygen (PaO~2~)/oxygen concentration (FiO~2~) ≤300mmHg.

Patients with "\>50% lesions progression within 24 to 48 hours in pulmonary imaging" should be treated as severe cases.

5. Differential diagnosis {#s0025}
=========================

Differential diagnosis should be performed according to mild affected cases by 2019-nCoV and COVID-19.

For example, the mild manifestations caused by COVID-19 should be distinguished from respiratory infections caused by other viruses. COVID-19 should be distinguished from viral pneumonia caused by influenza virus, adenovirus or respiratory syncytial virus, and mycoplasma pneumonia.

"Especially for suspected cases, rapid antigen detection, multiple PCR nucleic acid test and other methods should be adopted to examine common respiratory pathogens." are highlighted in this edition.

6. Case identification and report {#s0030}
=================================

The "disposal requirements for clinical diagnosed case in Hubei Province" is deleted.

In addition, "Exclusion Criteria for Suspected Cases" is also deleted. Standards of release of isolation for suspected cases are corresponded with "Removal Standards of Isolation of Confirmed Case".

7. Treatment {#s0035}
============

7.1. Determine the treatment place according to the severity of the disease {#s0040}
---------------------------------------------------------------------------

The "Suspected cases and confirmed cases" is deleted and "Cases should be isolated and treated in designated hospitals with effective isolation and protective conditions. Confirmed cases can be admitted to the same ward." is added.

7.2. Antiviral treatment {#s0045}
------------------------

The description of "no effective antiviral treatment is currently confirmed" is deleted. "Chloroquine phosphate (500mg for adult, twice per day)" and "Arbidol (200mg for adult, three times per day)" are added as trial drugs. Combinations of ribavirin and interferon or lopinavir/ritonavir are recommended. The course of treatment with trial drugs should be ≤10 days. Effects of trial drugs are recommended to be evaluated during clinical usage. Simultaneously use of three or more types of antiviral drugs is not recommended and relative drug treatment should stop if unbearable side effects occur.

7.3. Treatment for severe and critical cases {#s0050}
--------------------------------------------

"Convalescent plasma therapy" is added and recommended for treating rapidly developed cases, severe cases and critical cases. Administrations and dosage refer to *Clinical Plasma Therapy Plan for Corona Virus Disease 2019 Convalescents during Recovery* (*Tentative First Edition*).

7.4. Other treatments {#s0055}
---------------------

"Extracorporeal blood purification technology should be considered if possible" is changed to "Plasma change, adsorption, perfusion, blood/plasma filtering and other extracorporeal blood purification technologies should be considered if possible" for critical cases with severe inflammatory reactions.

7.5. Chinese medicine treatment {#s0060}
-------------------------------

The *Diagnosis and Treatment Plan of Corona Virus Disease 2019* (*Tentative Fifth Revised Edition*) is modified and complemented based on the in-depth observation and treatment of cases, summary and analysis of national-wide prescriptions of traditional Chinese medicine, screening effective experiences and prescriptions, and announcement of the *Recommendation of Lung-Clearing and Detoxification Soup in the Treatment of Corona Virus Disease 2019 by Integrated Traditional Chinese and Western Medicine*, the *Diagnosis and Treatment Plan of Severe and Critical Corona Virus Disease 2019 Cases* (*Tentative Second Edition*), and the *Management Regulation of Mild and General Corona Virus Disease 2019 Cases*. The classifications of stages of disease are consistent with the fifth revised edition and the traditional Chinese medicine treatment is divided into medical observation period and clinical treatment period (for confirmed cases), which is further divided into mild, general, severe, critical and recovery periods. Chinese patent medicine is recommended for medical observation period therapy while commonly used prescription, lung-clearing and detoxification soup is recommended for clinical treatment period. Interpretations of clinical manifestations, recommended prescription and dosage and intake methods are provided separately for mild, general, severe, critical and recovery periods. The specific usages of Chinese patent medicine (including traditional Chinese medicine injection) for severe and critical cases are added in the meantime. Different regions can refer to the recommended prescriptions for dialectical treatment according to the disease conditions, local climate characteristics, and different physical conditions.

8. Release of isolation and notes after discharge {#s0065}
=================================================

8.1. Release of isolation should meet with the following four standards {#s0070}
-----------------------------------------------------------------------

a\. Having normal body temperature for more than 3 days;

b\. With significantly recovered respiratory symptoms;

c\. Lung imaging shows obvious absorption and recovery of acute exudative lesion;

d\. With negative results of the nucleic acid tests of respiratory pathogens for consecutive twice (sampling interval at least 1 day).

8.2. "Notes after discharge" is added as follows {#s0075}
------------------------------------------------

a\. Designated hospitals should strengthen communication with basic medical institutions in patients' residence, share medical records, and forward information of discharged cases to relevant neighborhood committee and basic medical institutions.

b\. Discharged cases are recommended for continuously health monitor for 14 days, wearing facial masks, living in a ventilated single room, reducing frequency of close contact with family members, eating alone, keeping hand hygiene and avoiding outdoor activities due to the compromised immunome and risk of infecting other pathogens.

c\. A follow-up and return visit in the second and fourth weeks respectively after discharge is recommended.
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